Abbott has voluntarily agreed to pull Meridia (Sibutramine) off the market because it increased the risk of stroke and heart attacks. The Sibutramine Cardiovascular Outcomes (SCOUT) trial found that patients who took sibutramine had a 16% increased risk of a cardiovascular event compared to those who took a placebo.
“Meridia’s continued availability is not justified when you compare the very modest weight loss that people achieve on this drug to their risk of heart attack or stroke,” said John Jenkins, M.D., director of the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research (CDER). “Physicians are advised to stop prescribing Meridia to their patients and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.”
Read more here.